cyrilzakka/clinical-trials huggingface dataset:
Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura.

1. To determine the incidence, prevalence and long-term outcome of patients with SFTP in the German spoken part of Switzerland.
2. To define the role of immunohistochemical and molecular techniques, such as immunostaining, FISH and mutational analysis regarding their ability to predict malignant behavior in terms of prediction of overall survival and disease-free survival.

Retrospective observational study on patients with SFPT in the German spoken part of Switzerland between 2000 and 2011 (approximately 300 patients):

Phase 1) Information leaflet (letter of invitation) from study center (University Hospital of Zurich) to the institutes for pathology from all university, cantonal and city hospitals in the German spoken part of Switzerland. Patient recruitment performed by medical staff from the aforementioned institutes for pathology.

Phase 2) Obtaining first orally (by telephone) and thereafter written informed consent from the patients performed by medical staff from the aforementioned institutes for pathology.

Phase 3) After written and oral consent has been given, a doctoral candidate (member of the study group, student of the University of Zurich) will perform the data entry based on clinical and histological records locally at each external institute for pathology (no patient record files will be copied or transferred in original to the University Hospital of Zurich). Data entry in the electronic case report from (excel file on study laptop) will be performed with anonymous data only. Hence, each patient will have a study number containing the treating hospital, year of diagnosis and a consecutive number (e.g. KSSG-2011-1, KSSG-2011-2, STZ-2007-1, STZ-2007-2, ...). No names or birth dates will appear in the case report form.

Provided that informed consent is given, patient follow-up will be performed by contacting the primary care physician (general physician or family doctor) by telephone, which is handled by the doctoral candidate.

Deceased patients will not be incorporated within the study.

Phase 4) Review of the histological specimen which are collected by the aforementioned doctoral candidate and brought to the University Hospital of Zurich, Institute for Pathology, where immunohistochemical/molecular examinations, such as immunostaining, fluorescence in situ hybridization (FISH) and mutational analysis of the histological specimen are performed by PD Dr. A. Soltermann, member of the study team. After this, the specimens are returned to the original institute for pathology, where they were taken. All specimens are made anonymous at the moment of collection at the external hospital by the doctoral candidate (each specimen is labeled with the aforementioned study number, which is assigned in the case report form).

Phase 5) Data analysis, publication.

Eligibility Criteria:
Inclusion criteria:

* Histologically proven diagnosis of SFTP between 2000 and 2011.

Exclusion criteria:

* Missing informed consent
Radioembolization for Hepatocellular Carcinoma With Portal Vein Tumoral Thrombosis

In patients with hgepatocellular carcinoma (HCC) and portal vein tumoral thrombosis (PVTT), Sorafenib represents the treatment of choice but more recently, trans-arterial radioembolization (TARE) with yttrium-90 has been also proposed. A considerable percentage of such patients are not only able to achieve stability of the disease, but also to obtain a complete radiological response (CR). The possibility of achieving a CR might allow these patients to be listed for liver transplantation (LT), in order to cure not only the cancer but also the underlying cirrhosis that generated it.


Eligibility Criteria:
Inclusion Criteria:

1. diagnosis of HCC;
2. age ≥ 18 years;
3. performance status according to Eastern Cooperative Oncology Group 0-1;
4. preserved liver function (Child-Pugh score ≤B7);
5. PVTT limited to the first order portal branch.

Exclusion Criteria:

1. any contraindication to TARE treatment;
2. macrovascular invasion extended to the main portal trunk and/or to the contralateral portal branch;
3. presence of extra-hepatic disease
Comparative Study of Menstrual Blood and Systemic Blood

The purpose is to investigate how menstrual blood differs from systemic blood to evaluate if menstrual blood could be utilized as a natural and non-invasive access to blood for regular health monitoring and early diagnostics.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-45

Exclusion Criteria:

* weigh less then 110 pounds
* currently on a birth control method
Identification and Treatment of Cervical Abnormalities in Perú Through Integration of Pocket Colposcopy and Telemedicine

The Pocket colposcope has 510k FDA clearance and has been successfully used in almost 1500 unique patients globally in Duke and non-Duke protocols to date. The objective is to provide colposcopy capability to rural communities in Peru potentially using Telehealth. Approximately 10,000 women will receive self HPV test kit for community health workers. Of these participants, approximately 1,000 HPV+ participants will be invited to participate in this pocket colposcopy study. Approximately 500 of these participants may require treatment using thermocoagulation.

The goal is to demonstrate that the combination of self-sampling, the Pocket colposcope and the thermocoagulator will yield a high proportion of HPV positive women who complete treatment and follow-up care. The bulk of this trial will occur over a two-year period in Peru. Duke will provide the Pocket colposcope and the Calla application to run the device only. Dr. Garcia will recruit and train community women for the distribution of self-collection HPV test kits, identify and partner with 10 to 12 health centers in the Andean region of Peru, conduct baseline data collection in each health center, procure necessary equipment and technology, and conduct training for HPV testing, Pocket colposcopy, and thermocoagulation. Within 18 months trained community women will distribute 10,000 HPV tests to women within the region. The investigators anticipate that 10% of the women screened will be HPV positive and they will be recruited for our trial. As part of the study the participants will be followed to determine if the participants attend a health center, receive Pocket colposcopy, and if needed whether the participants are treated with the thermocoagulator device. All women will be appointed to return to the health center for a follow-up evaluation six months post-treatment.

Eligibility Criteria:
Inclusion Criteria:

* HPV+ pap smear
* Women must between the ages of 30-49yo

Exclusion Criteria:

* HPV (-) pap smear
* people without a cervix
Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

The purpose of the study is to find out if a study agent called Lumason® microbubbles may be helpful for people with lesions in the liver. It is possible it may help determine an early response to radioembolization and/or help demonstrate radiation toxicity to the surrounding liver.


Eligibility Criteria:
Inclusion Criteria:

* Provision of signed and dated informed consent form
* Stated willingness to comply with all study procedures and availability for the duration of the study
* Men and women \>18 years of age.
* Histologically or cytologically confirmed hepatocellular carcinoma or meet imaging criteria for a diagnosis of hepatocellular carcinoma with tumor burden dominant in the liver.
* Participants must have measurable disease, by CT or MRI per mRECIST, not be a candidate for surgical resection based on unresectability, anatomy, anesthesia risk, patient preference.
* Serum Bilirubin ≤ 2.0
* Platelet count \> 50,000/ul (corrected if needed)
* INR ≤ 1.5 (corrected if needed) 9. Serum creatinine \< 2.0 mg/dl

Exclusion Criteria:

* Participants must be at least one month beyond prior chemotherapy, ablation or surgery, and have recovered from all therapy-associated toxicities.
* History of severe allergic reaction to intravenous contrast media (iodinated and gadoliniumbased) or any agents used during the embolization; participant cannot be medicated against allergic reaction prior to embolization or contrast enhanced ultrasound.
* History of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason® microbubbles
* Active infection
* Participants with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)
* Pregnancy or lactation. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
* Participants may not be receiving any other investigational agents
Developmental Effects of Infant Formula Supplemented With LCPUFA

The purpose of this study is to compare the effects on visual development, growth, cognitive development, tolerance, and blood chemistry parameters in term infants fed one of four study formulas containing various levels of DHA and ARA.


Eligibility Criteria:
Inclusion Criteria:

* healthy, term, formula fed infants from 1-5 days of age

Exclusion Criteria:

* history of disease that effects normal growth and development
* breast fed, or formula intolerance
Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.


Eligibility Criteria:
Inclusion Criteria:

* 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis 3. Treated with ICIs

Exclusion Criteria:

* 1.Patients with a clear driver mutation that can be targeted for first-line treatment
Sentinel Lymph Node Detection in Prostate Surgery by Laparoscopy

In this study the investigators want to determine if the detection of lymph node is applicable in prostatectomy by laparoscopy.


Eligibility Criteria:
Inclusion Criteria:

* Age\> 18 years
* Diagnosis of invasive cancer of the prostate (T1 or T2 or T3)
* PSA ≥ 4,
* Gleason ≥ 6
* No treatment prior to surgery
* Indication of lymphadenectomy by coeliscopique
* ECOG or Karnofsky index 2
* Patient information and signed informed consent

Exclusion Criteria:

* neoadjuvant hormone therapy
* Interventions prior pelvic
* Patients who received anterior resection of part of prostate
* Patient or denied having an altered mental status
* Any contre indication to laparoscopy
A "Less-rapid" Sequence Anesthetic Induction/Intubation Sequence? Does Apneic Oxygenation by Means of an Oxygenating Laryngoscope Blade Prolong the "Duration of Apnea Without Desaturation" in Paralyzed Non-obese and Morbidly Obese Patients?

The study will test the efficacy of the Pentax AWSTM video laryngoscope (VLS) equipped with a P Blade (Figure 1) as the means to provide Apneic Oxygenation (AO) and prolong Duration of Apnea Without Desaturation (DAWD) in non-obese and morbidly obese females.

Pre-oxygenation/de-nitrogenation for three minutes of spontaneous breathing or alternatively four to eight deep breaths prior to rapid sequence anesthetic induction/intubation (RSII) in patients with healthy lungs, low oxygen demands and normal hemoglobin levels allows up to eight minutes of safe apnea time or DAWD.

The study will test the efficacy of the Pentax AWSTM video laryngoscope (VLS) equipped with a P Blade as the means to provide apneic oxygenation and prolong DAWD. The P Blade sports a suction conduit which can equally well provide a conduit for oxygen administration. The initial phase of the study will include non-obese healthy (ASAR 1-2) women patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery. Subsequently a cohort of morbidly obese patients (BM I ≥ 40 kg/m2) also requiring gynecologic abdominal access will be recruited for investigation.

Participants of each group (obese, non-obese) will be randomized to apneic oxygenation with the the Pentax AWS Laryngoscope or no apneic oxygenation.

Eligibility Criteria:
Inclusion Criteria:

1. Female patients,
2. American Society of Anesthesiologists Rating 1-2,
3. Aged 18 through 65 years of age
4. Elective gynecological surgery via an abdominal approach (laparoscopic or open)
5. Already consented to general anesthesia necessitating endotracheal intubation.
6. Are candidates for anesthesia using laryngeal mask airway if needed

Exclusion Criteria:

1. Patient refusal to enter study
2. History of difficult mask ventilation
3. History of, or anticipated difficult intubation
4. Heavy Smokers (\> 10 cigarettes per day)
5. Asthma
6. Chronic Obstructive Pulmonary Disease
7. Heart Disease
8. Renal or Liver disease
9. Neurological disease.
10. Women scored at ≥ 3/4 on the modified Mallampati scale 30.
11. Women exhibiting other signs of a potential difficult intubation (limited neck flexion or extension; neck circumference \> 30 cm; prominent incisors)
12. Patients with a baseline resting oxygenation level of less than 95%.
The Effect of Remote Ischemic Preconditioning in Aortic Valve Replacement Surgery

The study objective is to verify if a non-invasive remote ischemic preconditioning procedure (blood pressure cuff on the arm) is cardioprotective when applied before an aortic valve replacement surgery.


Eligibility Criteria:
Inclusion Criteria:

* Planned isolated aortic valve replacement (stenosis based)
* Age ≥ 18 years

Exclusion Criteria:

* Pregnancy
* Left ventricular dysfunction (LVEF\< 50%)
* Myocardial Infarct (\< 7days)
* Coronary artery disease (documented with \>50% stenosis)
* Coronary artery bypass grafting
* Chronic renal insufficiency (creatinine \>175 mmol/L or dialysis)
* Endocarditis
* Sternotomy redo
* Deep vein thrombosis to the compressed limb
* Emergency procedure
* TAVI procedure
* Planned off pump coronary artery bypass
* MAZE procedure
Efficacy of VR Educational Program on Empathy and Attitudes Toward Dementia in Caregivers

This study aims to evaluate the effect of VR educational program on improving attitude and empathy toward dementia among caregivers. We plan to recruit around 600 participants and randomly assign them to either a control group or an experimental group. The experimental group will participate in a dementia educational program combining VR lasting approximately 2-3 hours. Data would be collected from related questionnaires to investigate whether combining VR with dementia education can effectively improve participants' empathy and attitude toward dementia.

This study aims to evaluate the effect of VR educational program on improving attitude and empathy toward dementia among caregivers. We plan to recruit around 600 participants and randomly assign them to either a control group or an experimental group. The control group will receive traditional education on dementia which is primarily taught by instructors. The experimental group will participate in a dementia educational program combining VR lasting approximately 2-3 hours. The virtual reality educational modules predominantly offer first-person narratives that delineate various symptoms associated with dementia. Before, immediately after, and 4 weeks after the traditional and VR educational program, all participants will be asked to complete questionnaires about dementia empathy and attitude to explore whether combining VR with dementia education can effectively improve participants' empathy and attitude toward dementia.

Eligibility Criteria:
Inclusion Criteria:

1. Over 20 years;
2. Speak Chinese;
3. Take care of people with dementia currently.

Exclusion Criteria:

1. Those who are unable to use VR devices due to certain physical or mental situations;
2. Those who have fear/disgust for VR devices;
3. Those who feel dizzy after using VR devices;
4. The individual with dementia is currently residing in a care facility.
Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection

Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce emergence of resistant strains. Several new therapeutic agents are currently in development, however combination therapy trials in the HBV-infected population have only recently commenced. No such trials have been undertaken in the HIV/HBV co-infected population.

The primary study objective is to compare HBV DNA suppression to levels below the limit of detection (\<400 copies/ml) by week 48 in each treatment group. Virological and clinical anti-HBV efficacy of tenofovir and emtricitabine in antiretroviral naive patients with HIV/HBV co-infection.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)
* Age 18 - 70 years
* HBV DNA \> 106 copies/ml
* HBsAg positive for \> 6 months

In case documented duration of HBsAg seropositive is less than 6 months (this situation is most likely to occur in patients newly presenting to the HIV-outpatient clinic) the patient is eligible if the patient is:

1. HBsAg positive and
2. HBc core IgM antibody negative and
3. the liver biopsy gives evidence for a chronic active hepatitis. Thus making it likely that this patient has acquired the HBV infection more than 6 months ago.

   * ALT \< 10 x ULN
   * Creatinine \<= 2.0mg/dl
   * Platelet count \>= 50,000/mm3
   * HIV-1 therapy naive
   * No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN treatment allowed

Exclusion Criteria:

* HCV-RNA positive or Anti-HAV IgM positive
* Acute hepatitis (serum ALT \> 1000 U/L)
* Prior LAM, TDF, or ADV therapy
* Active opportunistic infection
* Other causes of chronic liver disease identified ( autoimmune hepatitis, haemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)
* Concurrent malignancy requiring cytotoxic chemotherapy
* Decompensated or Child's C cirrhosis
* Alfa-fetoprotein (AFP) \> 3X ULN (unless negative CT scan or MRI within 3 months of entry date)
* Pregnancy or lactation
* Any other condition which in the opinion of the investigator might interfere with compliance or outcome of the study
Evaluation of the Relationship Between Neck Pain and Temporomandibular Disorders in Office Workers

The current study aimed to explore the associations between neck pain and temporomandibular disorders in office workers

This is a cross-sectional study. All participants will provide informed consent before participating in the study. The study will be conducted in accordance with the Helsinki Declaration criteria. Data will be collected using questionnaires, which include information on demographic, clinical conditions.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 18 and 55,
* Working on computer,
* Having neck pain at least three months.

Exclusion Criteria:

* Reporting pregnancy,
* Having a history of accidents,
* Trauma or surgery in the neck region and temporomandibular region,
* Congenital anomaly of the spine or temporomandibular joint,
* Rheumatologic disease,
* Osteoporosis,
* Spondylosis,
* Spondylolisthesis,
* Infection of the spine or temporomandibular joint
* Cervical disc herniation,
* Tumor
Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.

To study Fibrocytes in patients with Rheumatoid Arthritis, Interstitial lung disease and severe asthma and healthy controls.

Objectives: 1) To demonstrate that circulating CD45+ CD34+ CD11b+ cells can express Procollagen 1 and thereby show that these markers can be used to identify circulating fibrocytes. 2) To measure the levels of circulating CD45+, CD34+, CD11b+ cells in patients with RA, Fibrotic ILDs, severe asthma and in healthy controls (HC). 3) To compare the levels with number of peripheral blood mononuclear cells (PBMC) that differentiate to mature fibrocytes in vitro.

Method: The CD45+, CD34+, CD11b+ cells from 4 patients were isolated by cell sorting, and stained for Procollagen. 30 patients (10 of each RA, fibrotic ILDs: IPF or non-specific interstitial pneumonitis (NSIP), severe asthma) and 10 HC were included. Current medication, disease activity, lung function and radiographic data were collected. In 100 µL of lysed blood cells were enumerated by flowcytometry. Further, PBMC were isolated and cultured for 5 days. Coverslips from two wells were stained and mature fibrocytes counted and reported as fibrocytes per 106 PBMC originally added to the well.

Eligibility Criteria:
Inclusion Criteria:

* 10 patient with rheumatoid arthritis.
* 10 patient with rheumatoid arthritis and interstitial lung disease
* 10 patients with interstitial lung disease (idiopathic pulmonary fibrosis or nonspecific interstitial pneumonia)
* 10 patients with asthma
* 10 healthy volunteers

Exclusion Criteria:

* Unable to sign written informed consent to participate in the study.
Correlation Between Preeclampsia and Positive for Obstructive Sleep Apnea Screening Test: STOPBANG Questionnaire

The purpose of this study is to find the correlation between high risk OSA (obstructive sleep apnea) patient, based on Stop-bang screening tool and preeclampsia

Obstructive sleep apnea (OSA) has been associated with preeclampsia and intrauterine growth retardation (IUGR).

Since the gold standard diagnosis of OSA is polysomnogram which is limited by cost and availability. Therefore, various screening tools were proposed in order to identify high risk OSA patient such as Stop-bang questionnaire.

From the previous study, Stop-bang showed a high predictive performance and the score equal or higher than 3 determines high risk for OSA.

Eligibility Criteria:
Inclusion Criteria:

- Pregnant women who were scheduled for cesarean delivery or admitted to the antepartum unit at Ramathibodi hospital

Exclusion Criteria:

* Age \< 18 year old
* Previous diagnose OSA
* Patients who have used continuous positive airway pressure (CPAP) or bi-level positive airway pressure (Bi-PAP) fro OSA treatment
Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial

Positive Psychotherapy for Smoking Cessation (PPT-S) addresses an array of risk factors for poor smoking outcomes (low positive affect, depressive symptoms, and cynical cognitions), while also providing skills that may buffer against stress and negative affect. The overall objective of this project is to conduct a randomized controlled trial to test the efficacy of PPT-S, enhanced with text messaging, compared to a time-matched behavioral smoking cessation treatment. Participants in both treatment conditions will receive nicotine replacement therapy and a validated text-messaging intervention for smoking cessation that monitors progress in quitting smoking and extends smoking counseling outside of the individual face-to-face context.


Eligibility Criteria:
Inclusion Criteria:

1. be 18 years of age or older
2. smoke at least 5 cigarettes per day for longer than one year with no current regular use of other nicotine/tobacco products including e-cigarettes
3. have a baseline carbon monoxide level of at least 4 ppm
4. be willing to use the nicotine patch
5. report at least a 5 on a 0 to 10 scale rating the importance of quitting smoking (where 10 = extremely important);
6. have an active cell phone and be willing to send and receive text messages for the duration of the intervention.

Exclusion Criteria:

1. Contact study site for details